Pathology Laboratory Utilization Manager, Special Testing Manager, Physician/Laboratory Consultant, Director of Specimen Referral, Adjunct Assistant Professor
BIOGRAPHY
SEP 23, 2021 11:00 AM PDT
Share
Updates on Primary Aldosteronism Screening and Use of Direct Renin
Speaker
Abstract
Date: September 23, 2021
Time: 11:00am (PDT), 2:00pm (EDT)
Primary aldosteronism (PA) is the most common form of secondary hypertension, caused by hyperactivity in one or both of the adrenal glands that leads to inappropriate aldosterone production. The prevalence of PA among general and resistant hypertensive populations ranges from 5-20%. PA is considered highly treatable and potentially curable. As such, the Endocrine Society guidelines recommend screening for PA in high risk populations using the plasma aldosterone/plasma renin ratio (ARR). It is generally accepted that both the plasma renin and aldosterone levels tend to fall with advancing age and plasma renin decreases more than aldosterone; consequently, the ARR increases in the elderly which supports the need for age-specific ARR cutoffs. Traditionally, renin has been measured by a plasma renin activity (PRA) radioimmunoassay or liquid chromatography tandem mass spectrometry (LC-MS/MS). Direct renin concentration (DRC) immunoassays, also known as plasma renin concentration (PRC), have recently become more popular because of numerous benefits including walk-away automation, shorter turnaround times, and excellent reproducibility compared to PRA. In this webinar, we will review the key differences between PRA and DRC assays and discuss the utility of proposed age-specific ARR cutoffs for PA screening calculated using direct renin measurement.
Learning Objectives:
Time: 11:00am (PDT), 2:00pm (EDT)
Primary aldosteronism (PA) is the most common form of secondary hypertension, caused by hyperactivity in one or both of the adrenal glands that leads to inappropriate aldosterone production. The prevalence of PA among general and resistant hypertensive populations ranges from 5-20%. PA is considered highly treatable and potentially curable. As such, the Endocrine Society guidelines recommend screening for PA in high risk populations using the plasma aldosterone/plasma renin ratio (ARR). It is generally accepted that both the plasma renin and aldosterone levels tend to fall with advancing age and plasma renin decreases more than aldosterone; consequently, the ARR increases in the elderly which supports the need for age-specific ARR cutoffs. Traditionally, renin has been measured by a plasma renin activity (PRA) radioimmunoassay or liquid chromatography tandem mass spectrometry (LC-MS/MS). Direct renin concentration (DRC) immunoassays, also known as plasma renin concentration (PRC), have recently become more popular because of numerous benefits including walk-away automation, shorter turnaround times, and excellent reproducibility compared to PRA. In this webinar, we will review the key differences between PRA and DRC assays and discuss the utility of proposed age-specific ARR cutoffs for PA screening calculated using direct renin measurement.
Learning Objectives:
- Provide an overview of the renin-angiotensin-aldosterone system (RAAS) and implication on Hypertension.
- Describe and understand key differences between plasma renin activity (PRA) assays and direct renin concentration (DRC) assays.
- Discuss proposed age-specific plasma aldosterone/plasma renin ratio (ARR) cutoffs for PA screening calculated using DRC.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
You May Also Like
SEP 17, 202112:00 PM CST
C.E. CREDITS
SEP 17, 202112:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
SEP 14, 20217:00 AM PDT
C.E. CREDITS
SEP 14, 20217:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
DEC 01, 20217:00 AM PST
C.E. CREDITS
DEC 01, 20217:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
SEP 16, 20218:00 AM PDT
C.E. CREDITS
SEP 16, 20218:00 AM PDT
Date: September 16, 2021 Time: 8:00am (PDT), 11:00am (EDT) Rapid screening and speed of scale-up in protein therapeutics are critical factors in today’s biotech and pharma workflows. T...
DEC 07, 202110:00 AM PST
C.E. CREDITS
DEC 07, 202110:00 AM PST
Date: December 07, 2021 Time: 10:00am (PST) The RNAscope™ technology allows high sensitivity and spatial resolution providing pivotal single-cell information to gain better insights in...
JUN 24, 20218:00 AM PDT
C.E. CREDITS
JUN 24, 20218:00 AM PDT
Date: June 24, 2021 Time: 8:00am (PDT), 11:00am (EDT) Cardiovascular disease is a leading health problem, affecting almost 30% of individuals in the developed world, and comprises a wide ran...
Loading Comments...
Finish Registering
-
JAN 10, 2022Bionano Genomics 2022 Symposium -
JAN 25, 2022Lab Compliance Connect
-
FEB 23, 2022Drug Discovery & Development 2022
-
MAR 10, 2022Neuroscience 2022
-
MAR 23, 2022Cannabis Sciences 2022
- See More
-
DEC 12, 2021
-
DEC 12, 2021
- See More
